Cre-dependent DREADD (Designer Receptors Exclusively Activated by Designer Drugs) mice

Hu Zhu, Dipendra K. Aryal, Reid H.J. Olsen, Daniel J. Urban, Amanda Swearingen, Stacy Forbes, Bryan L. Roth, Ute Hochgeschwender

Research output: Contribution to journalArticlepeer-review

109 Scopus citations


DREADDs, designer receptors exclusively activated by designer drugs, are engineered G protein-coupled receptors (GPCR) which can precisely control GPCR signaling pathways (for example, Gq, Gs, and Gi). This chemogenetic technology for control of GPCR signaling has been successfully applied in a variety of in vivo studies, including in mice, to remotely control GPCR signaling, for example, in neurons, glia cells, pancreatic β-cells, or cancer cells. In order to fully explore the in vivo applications of the DREADD technology, we generated hM3Dq and hM4Di strains of mice which allow for Cre recombinase-mediated restricted expression of these pathway-selective DREADDs. With the many Cre driver lines now available, these DREADD lines will be applicable to studying a wide array of research and preclinical questions. genesis 54:439–446, 2016.

Original languageEnglish
Pages (from-to)439-446
Number of pages8
Issue number8
StatePublished - Aug 1 2016


  • G protein-coupled receptors
  • GsD
  • chemogenetic
  • hM3Dq
  • hM4Di


Dive into the research topics of 'Cre-dependent DREADD (Designer Receptors Exclusively Activated by Designer Drugs) mice'. Together they form a unique fingerprint.

Cite this